{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:45:56Z","timestamp":1793889956380,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex\u2019s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kuur Therapeutics; Cookies for Kids\u2019 Cancer Foundation"},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kuur Therapeutics"},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP160283"],"award-info":[{"award-number":["RP160283"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41591-020-1074-2","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T12:07:04Z","timestamp":1602504424000},"page":"1686-1690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":282,"title":["Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4263-9115","authenticated-orcid":false,"given":"Andras","family":"Heczey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy N.","family":"Courtney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Montalbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-8852","authenticated-orcid":false,"given":"Ka","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Ghatwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Dakhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Raveh-Sadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-8543","authenticated-orcid":false,"given":"Cynthia N.","family":"Chauvin-Fleurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-8782","authenticated-orcid":false,"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho","family":"Ngai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica J.","family":"Di Pierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-8526","authenticated-orcid":false,"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-6630","authenticated-orcid":false,"given":"Leonid S.","family":"Metelitsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri1309","volume":"4","author":"DI Godfrey","year":"2004","unstructured":"Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. & Van Kaer, L. NKT cells: what\u2019s in a name? Nat. Rev. Immunol. 4, 231\u2013237 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"1074_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.immuni.2008.07.011","volume":"29","author":"AK Savage","year":"2008","unstructured":"Savage, A. K. et al. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29, 391\u2013403 (2008).","journal-title":"Immunity"},{"key":"1074_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.clim.2010.10.005","volume":"140","author":"LS Metelitsa","year":"2011","unstructured":"Metelitsa, L. S. Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans. Clin. Immunol. 140, 119\u2013129 (2011).","journal-title":"Clin. Immunol."},{"key":"1074_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1084\/jem.20031462","volume":"199","author":"LS Metelitsa","year":"2004","unstructured":"Metelitsa, L. S. et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199, 1213\u20131221 (2004).","journal-title":"J. Exp. Med."},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI37869","volume":"119","author":"L Song","year":"2009","unstructured":"Song, L. et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Invest. 119, 1524\u20131536 (2009).","journal-title":"J. Clin. Invest."},{"key":"1074_CR6","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","volume":"11","author":"T Tachibana","year":"2005","unstructured":"Tachibana, T. et al. Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11, 7322\u20137327 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1074_CR7","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","volume":"22","author":"F Cortesi","year":"2018","unstructured":"Cortesi, F. et al. Bimodal CD40\/Fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression. Cell Rep. 22, 3006\u20133020 (2018).","journal-title":"Cell Rep."},{"key":"1074_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"1074_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20042592","volume":"201","author":"DH Chang","year":"2005","unstructured":"Chang, D. H. et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201, 1503\u20131517 (2005).","journal-title":"J. Exp. Med."},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clim.2011.01.009","volume":"140","author":"S Motohashi","year":"2011","unstructured":"Motohashi, S., Okamoto, Y., Yoshino, I. & Nakayama, T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin. Immunol. 140, 167\u2013176 (2011).","journal-title":"Clin. Immunol."},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","volume":"23","author":"MA Exley","year":"2017","unstructured":"Exley, M. A. et al. Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial. Clin. Cancer Res. 23, 3510\u20133519 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1074_CR12","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey, A. et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood 124, 2824\u20132833 (2014).","journal-title":"Blood"},{"key":"1074_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo, A. et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell 34, 596\u2013610 (2018).","journal-title":"Cancer Cell"},{"key":"1074_CR14","doi-asserted-by":"publisher","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","volume":"167","author":"SM Tahir","year":"2001","unstructured":"Tahir, S. M. et al. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J. Immunol. 167, 4046\u20134050 (2001).","journal-title":"J. Immunol."},{"key":"1074_CR15","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1172\/JCI83476","volume":"126","author":"G Tian","year":"2016","unstructured":"Tian, G. et al. CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J. Clin. Invest. 126, 2341\u20132355 (2016).","journal-title":"J. Clin. Invest."},{"key":"1074_CR16","first-page":"5914","volume":"44","author":"G Schulz","year":"1984","unstructured":"Schulz, G. et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 44, 5914\u20135920 (1984).","journal-title":"Cancer Res."},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 25, 2214\u20132224 (2017).","journal-title":"Mol. Ther."},{"key":"1074_CR18","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1172\/JCI59535","volume":"122","author":"D Liu","year":"2012","unstructured":"Liu, D. et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J. Clin. Invest. 122, 2221\u20132233 (2012).","journal-title":"J. Clin. Invest."},{"key":"1074_CR19","doi-asserted-by":"crossref","unstructured":"Xu, X., et al. NKT cells co-expressing a GD2-specific chimeric antigen receptor and IL-15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin. Cancer Res. 25, 7126\u20137138 (2019).","DOI":"10.1158\/1078-0432.CCR-19-0421"},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","volume":"27","author":"SL Cohn","year":"2009","unstructured":"Cohn, S. L. et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J. Clin. Oncol. 27, 289\u2013297 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1074_CR21","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100\u20131109 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1084\/jem.20050732","volume":"202","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni, L. et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907\u2013912 (2005).","journal-title":"J. Exp. Med."},{"key":"1074_CR23","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","volume":"35","author":"JR Park","year":"2017","unstructured":"Park, J. R. et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 35, 2580\u20132587 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1200\/JCO.2012.45.8794","volume":"31","author":"B Decarolis","year":"2013","unstructured":"Decarolis, B. et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne Interscore Comparison Study. J. Clin. Oncol. 31, 944\u2013951 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1074_CR25","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.4049\/jimmunol.1800429","volume":"201","author":"H Ngai","year":"2018","unstructured":"Ngai, H. et al. IL-21 selectively protects CD62L+ NKT cells and enhances their effector functions for adoptive immunotherapy. J. Immunol. 201, 2141\u20132153 (2018).","journal-title":"J. Immunol."},{"key":"1074_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1603-1","volume":"19","author":"M Stoeckius","year":"2018","unstructured":"Stoeckius, M. et al. Cell hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol. 19, 224 (2018).","journal-title":"Genome Biol."},{"key":"1074_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902 (2019).","journal-title":"Cell"},{"key":"1074_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-019-1874-1","volume":"20","author":"C Hafemeister","year":"2019","unstructured":"Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. Genome Biol. 20, 296 (2019).","journal-title":"Genome Biol."},{"key":"1074_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1074_CR30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978\u2013985 (2018).","journal-title":"Nat. Med."},{"key":"1074_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"1074_CR32","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251\u20131259 (2019).","journal-title":"Nat. Med."},{"key":"1074_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1074-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T08:03:43Z","timestamp":1683705823000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-1074-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-1074-2","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.H., A.N.C., G.D. and L.S.M are co-inventors on pending patent applications that relate to the use of NKT cells in cancer immunotherapy and have been licensed by Baylor College of Medicine to Kuur Therapeutics for commercial development. Kuur Therapeutics provided research support for this project (to L.S.M.) via a sponsored research agreement with Baylor College of Medicine. A.M., S.R., K.L., M.L., N.G., O.D., B.L., T.R.-S., C.N.C.-F., X.X., H.N., E.J.D.P. and B.S. declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}